Guangzhou Today, China Tomorrow? A Closer Look At Reimbursement Pilots For Iressa, Tarceva
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca CEO Pascal Soriot sees tremendous potential for Iressa in China, where Roche’s Herceptin grew over 20% in 2012. Both companies have their high-priced targeted therapies in China’s first-ever reimbursement pilot in Guangzhou.
You may also be interested in...
Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
By Celia Deng, Zhiyi Tong and Paul Zhang
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.